Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.

Xiaoling Luo Mm Jing XuShoulian ZhouMm Cheng XueZewei ChenMm Zhiguo Mao

Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)

Among the therapeutic drugs with the potential risk of increasing serum potassium in diabetic kidney disease patients, MRA added an extra risk of hyperkalemia, while SGLT2i had the opposite effect and could even reverse the elevation of serum potassium caused by the combined regimen including MRA.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
contrast enhanced
type diabetes
peritoneal dialysis
patient reported outcomes
human health
drug induced